CY-9652

N/A

Report date: 2022/08/23 20:00:44
NME

Base Information

Drug NameCY-9652
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionT lymphocytes inhibitorsIntegrin alpha-4/beta-1 antagonists
TargetsIntegrin alpha-4/beta-1
Therapy Area/IndicationsMultiple SclerosisAsthmaArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEpimmune Inc
Active IndicationsN/A
Inactive IndicationsMultiple SclerosisAsthmaArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A